[Uterine pathology in women with breast cancer treated with tamoxifen].
Carcangiu
M L
ML
D000232:Adenofibroma / Q000139:chemically induced / Q000453:epidemiology; D018195:Adenosarcoma / Q000139:chemically induced / Q000453:epidemiology; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000139:chemically induced / Q000453:epidemiology; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D004965:Estrogen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006984:Hypertrophy; D007890:Leiomyosarcoma / Q000139:chemically induced / Q000453:epidemiology; D008593:Menopause; D008875:Middle Aged; D018200:Mixed Tumor, Mullerian / Q000139:chemically induced / Q000453:epidemiology; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000453:epidemiology / Q000473:pathology; D014599:Uterus / Q000187:drug effects / Q000473:pathology*
D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D013629:Tamoxifen